Polymer particles
Biodegradable, cross-linked polymer particle embolics and methods of making the same are described. The particle embolics can be used as embolization agents.
1. An embolic system including:
a syringe, a vial, or a combination thereof; and
polymer particles comprising at least one monomer including at least one functional group and at least one crosslinker having a structure
2. The embolic system of claim 1 , wherein the polymer particles have a diameter between about 40 μm and about 1,200 μm.
3. The embolic system of claim 1 , wherein the polymer particles have a diameter between about 75 μm and about 1,200 μm.
4. The embolic system of claim 1 , wherein the at least one functional group is acrylate, acrylamide, methacrylate, or methacrylamide.
5. The embolic system of claim 1 , wherein the at least one monomer includes an ionizable functional group.
6. The embolic system of claim 5 , wherein the ionizable functional group is basic.
7. The embolic system of claim 5 , wherein the ionizable functional group is acidic.
8. The embolic system of claim 1 , wherein the polymer particles include a second crosslinker including a second linkage selected from an ester, a thioester, a carbonate, a peptide cleavable by matrix metalloproteinases, a peptide cleavable by matrix collagenases, a peptide cleavable by matrix elastases, and a peptide cleavable by matrix cathepsins.
9. The embolic system of claim 1 , wherein the polymer particles are biodegradable.
10. The embolic system of claim 1 , wherein the polymer particles are substantially degraded within about 1 months of implantation.
11. The embolic system of claim 1 , wherein the at least one monomer is dimethylacrylamide.
12. The embolic system of claim 1 , wherein the at least one monomer is acrylamide.
13. A method of treatment, the method comprising:
delivering a solution including polymer particles through a delivery device to a treatment site,
wherein the polymer particles include at least one monomer including at least one functional group and at least one crosslinker having a structure
14. The method of claim 13 , wherein the polymer particles have a diameter between about 40 μm and about 1,200 μm.
15. The method of claim 13 , further comprising:
mixing a radiopaque contrast agent with the polymer particles.
16. The method of claim 13 , wherein the delivering is through a catheter, a microcatheter, or a needle.
17. The method of claim 13 , further comprising:
occluding blood flow using the polymer particles.
18. The method of claim 13 , wherein the polymer particles include a second crosslinker including a second linkage selected from an ester, a thioester, a carbonate, a peptide cleavable by matrix metalloproteinases, a peptide cleavable by matrix collagenases, a peptide cleavable by matrix elastases, and a peptide cleavable by matrix cathepsins.
19. The method of claim 13 , wherein the polymer particles are biodegradable.
20. The method of claim 19 , wherein the polymer particles are substantially degraded within about 6 months of implantation.